…cribed Ursodeoxycholic acid (UDCA), Obeticholic acid (OCA), and Bezafibrate (BZA), has shown biochemical benefit in patients with inadequat…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 66 of 2459…dmission with HE 1 (8%) Pre-admission TIPS 1 (8%) Pre-admission Rifaximin 12 (92%) Pre-admission Lactulose 11 (85%) Grade HE on presentat…
…cer, although there remains a need for improvement in efficacy. Fruquintinib, an oral and highly selective vascular endothelial growth facto…
…monocyte ratio, lymphocyte/monocyte ratio) did not discriminate PsA, RA or HC. After 1 year, C3 and S100A8/9 decreased significantl…
… and without a diagnosis of POAG prior to diabetes diagnosis or metformin use. Bivariate logistic regression, multivariable logistic regr…
…in, A/B+INTESTIFIX 001 in comparison to vancomycin-placebo, A/B+INTESTIFIX 001-placebo and safety of the therapeutic combination in advanced HCC. INTE…
…their intentions to refer for imaging or use electrotherapy for low back pain even if the language of the recommendations is optimised. While…
…ptidase-4 inhibitors (DPP-4is) and (2) metformin monotherapy in type 2 diabetes among subjects with a diabetes duration of <5 years at cohort e…
…diagnosis 7 26% 22/27 (81%) used a thiopurine prior to starting methotrexate. The reasons for switch to methotrexate were failure of disease…
… bempedoic acid, and 2% received a combination of Ezetimibe and bempedoic acid. No patients were initiated on PCSK9 inhibitors.Abstract 7-007 …
…th the greatest reductions in LDL-C, followed by inclisiran and bempedoic acid.…
…rrythmias, cardiac hypertrophy, hypertension, dyslipidaemia and type 2 diabetes mellitus. Due to its lipophilic and hydrophobic nature Phe accumulates i…